Table 1 Characteristics of included studies
From: Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis
Study | Study type | Location | Year of enrolment | Number of patients | Intensive phase | Continuation phase | Patients receiving corticosteroids | Follow-up (months) | Patients characteristics | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Treatment | Duration (months) | Treatment | Duration (months) | Age (years) | Female | Lost-to-follow-up | HIV | |||||||
Hosoglu et al (1998) | RC | Turkey | 1985–1996 | 101 | HRSZ (group 1); HRSE (group 2) | 2–3 | HR | ≥ 6 | NR | NR (≥ 9) | 30.6 ± 13.0 | 40 | 5 | NR |
Katrak et al (2000) | PC | India | 1992–1997 | 53 | HRZE | ≥ 6 | NR | 6 | 16–60 | NR | 0 | 22 | ||
Chan et al (2003) | RC | China | 1997–2001 | 31 | HRZE | 3 | HR | 9 | NR | 12–60 | ≥ 14 | 17 | NR | 1 |
Thwaites et al (2004) | PC | Vietnam | 2001–2003 | 545 | HRZS (group 1); HRZE (group 2) | 3 | HRZ | 6 | Some | 9 | 15–88 | 214 | 34 | 98 |
Cagatay et al (2004) | RC | Turkey | 1991–2002 | 42 | HRZE | 2–3 | HR | 10 | Some | 12 | 16–60 | 28 | NR | 2 |
Torok et al (2008) | PC | Vietnam | 2004–2005 | 58 | HRZE (group 1); HRZES (group 2) | 3 | HRZ | 6 | NR | NR (≥ 9) | 20–48 | 7 | 8 | 36/55 |
Hsu et al (2010) | RC | China | 2000–2006 | 108 | HRZ (group 1); HRZE (group 2) | ≥ 6 | Some | ≥ 6 | 19–87 (54.9 ± 18.6) | 37 | NR | NR | ||
Sinha et al (2010) | PC | India | 2008–2009 | 101 | HRZS | 2 | HR | 7 | All | 6 | 14–85 (30 ± 13) | 42 | NR | 0 |
Anuradha et al (2010) | PC | India | 2008–2009 | 100 | HRZE | 2 | HR | 4 | All | 6 | > 14 (30 ± 13) | 41 | NR | 0 |
Sharma et al (2011) | RC | India | 2008–2010 | 158 | HRZS | 2 | HR | 7 | All | ≥ 9 | > 14 (31.95 ± 13.96) | 91 | NR | 0 |
Torok et al (2011) | RCT | Vietnam | 2005–2007 | 253 | HRZE (group 1); HRZES (group 2) | 3 | HR | 6 | All | ≥ 9 | ≥ 15 | 25 | NR | 253 |
Marais et al (2011) | RC | South Africa | 2009 | 120 | HRZE (group 1); HRZES (group 2) | 2–3 | HR (group 1); HRE (group 2) | ≥ 4 (group 1); ≥ 5 (group 2) | Some | ≥ 6 | ≥ 18 | 60 | 12 | 106/114 |
Raut et al (2013) | PC | India | 2010–2012 | 80 | HRZS | 2 | HR | 7 | NR | 6 | 14–68 | 37 | NR | 0 |
Ruslami et al (2013) | RCT | Indonesia | 2010–2011 | 60 | HRZE (group1); HRZMfx (group 2) | 2 | HR | 4 | All | ≥ 6 | > 14 | 27 | NR | 7 |
Imam et al (2014) | RC | Qatar | 2006–2012 | 80 | HRZE | ≥ 6 | Some | NR (≥ 6) | ≥ 18 | 15 | 1 | NR | ||
Iype et al (2014) | PC | India | 2010–2011 | 45 | HRZS (group 1); HREZ (group 2) | 2–3 | HR | 7 | NR | NR (≥ 9) | 14–61 | 21 | 2 | NR |
Chen et al (2014) | RC | China | 2002–2009 | 38 | HRZE | 2 | HRE | 10月16日 | Some | NR (12–18) | > 18 | 133 | 3 | 2 |
Jha et al (2015) | PC | India | 2012–2014 | 118 | HRZS | 2 | HR | 7 | All | 6 | ≥ 14 | 61 | NR | 0 |
Misra et al (2015) | RC | India | 2010–2014 | 74 | HRZE | 6 | HR | 12 | ALL | NR (≥ 18) | ≥ 14 | 28 | NR | NR |
Tai et al (2016) | PC | Malaysia | 2009–2014 | 41 | HRZE | 2 | HR | 10月16日 | Some | NR (12–18) | 35.0 ± 13.7 | 19 | NR | 0 |
Li et al (2017) | RC | China | 2012–2015 | 156 | HRZE | 2–4 | HR | 6月12日 | All | ≥ 8 | 16–82 | 69 | 14 | NR |
Raberahona et al (2017) | RC | Madagascar | 2007–2014 | 75 | HRZE (group 1); HRZES (group 2) | 2 | HR (group 1); HRZE (group 2) | 6 (before 2012); 4 (after 2012) | NR | NR (≥ 6) | ≥ 18 (35.4 ± 12.7) | 33 | NR | 3 |